Anti-acetylcholine receptor antibody (AChR-Ab) titers and the AChR-Ab rates of change correlated with myasthenia gravis ...

Recently approved treatments for generalized myasthenia gravis (gMG), including complement and neonatal Fc receptor (FcRn) ...

Heightened focus on delays in diagnosing generalized myasthenia gravis (gMG) follows the promise of better results for some patients with newer treatments that include complement inhibitors and ...

Sugammadex (Bridion; Merck) is a small-molecule oligosaccharide, also known as a modified gamma cyclodextin, that was ...

COUR Pharmaceuticals has been around a while, but not until last year did the company solidify behind its ultimate mission ...

THE occurrence of thyrotoxicosis in patients with myasthenia gravis is not rare, over 90 such cases having been reported since the turn of the century. 1,2 Various estimates place the incidence of ...

1 Department of Neurology, Peking University People’s Hospital, Beijing, China 2 Department of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China Background: ...

The FDA has approved Alexion's Soliris for use in patients with treatment resistant generalised Myasthenia gravis (gMG), making it the first new therapy for the condition in 60 years. The approval ...

Biopharma doubles down on immunology and inflammation as companies target new pathways and seek to improve on current options ...